SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016)

• R. de las Peñas ^[10] ; A. Blasco ^[1] ; J. De Castro ^[2] ; Y. Escobar ^[3] ; R. García-Campelo ^[4] ; A. Gúrpide ^[5] ; R. Lopez-Lopez ^[6] ; M. Majem ^[7] ; C. A. Rodríguez ^[8] ; J. A. Virizuela ^[9]
  1. [1] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  2. [2] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  3. [3] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  4. [4] Complexo Hospitalario Universitario da Coruña

     Complexo Hospitalario Universitario da Coruña

     A Coruña, España

     
  5. [5] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  6. [6] Complexo Hospitalario Universitario de Santiago

     Complexo Hospitalario Universitario de Santiago

     Santiago de Compostela, España

     
  7. [7] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  8. [8] Hospital Universitario de Salamanca

     Hospital Universitario de Salamanca

     Salamanca, España

     
  9. [9] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  10. [10] Consorcio Hospital Provincial de Castellón, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 18, Nº. 12 (December 2016), 2016, págs. 1237-1242
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Chemotherapy-induced nausea and vomiting is one of the most worrisome adverse effects of chemotherapy for cancer patients. It can cause severe discomfort and affect the quality of life. In recent years, the incorporation of new drugs has increased the efficacy of antiemetic treatments in the control of emesis associated with chemotherapy. This guideline, in which we give some treatment recommendations with level of evidence and grade of recommendation, provides an update of the previously published guideline of the Spanish Society of Medical Oncology and represents our continued commitment to improving supportive care in cancer patients.